Skip to main content
. 2016 Oct 31;6:36064. doi: 10.1038/srep36064

Figure 5. Immunization with MOG196-pulsed DCs suppressed MOG35-55-induced EAE.

Figure 5

(A) Experimental design for “B”: C57BL/6 mice were immunized with MOG35-55 for EAE. One week before and after the EAE induction, the animals received one of the following subcutaneous treatments: (1) no treatment (No Tx); (2) 1 × 106 Qdm-pulsed Kb−/−Db−/− DCs (DC/Qdm); (3) 1 × 106 MOG196-pulsed Kb−/−Db−/− DCs (DC/MOG196). The mice were then monitored for paralytic disease daily. (B) Daily mean disease score was shown. N = 5. *P < 0.05; **P < 0.01; ***P < 0.001. Two-way ANOVA test. (C) Experimental design for “D”: C57BL/6 mice were immunized with MOG35-55 for EAE on day 0. At days -3, 2, and 7, animals were immunized with 1 × 106 B6 DCs pulsed with Qdm (DC/Qdm), HSP60p216 (DC/HSP60p216), or MOG196 (DC/MOG196). The animals were then monitored for paralytic disease daily. (D) Daily mean disease score was shown. N = 5. *P < 0.05. Two-way ANOVA test. Concentration of peptides used for pulsing the DCs was 10 μg/ml.